Mostrar el registro sencillo del ítem
| Autor | Luetkemeyer, Anne F. | |
| Autor | Rosenkranz, Susan L. | |
| Autor | Lu, Darlene | |
| Autor | Grinsztejn, Beatriz | |
| Autor | Sanchez, Jorge | |
| Autor | Ssemmanda, Michael | |
| Autor | Sanne, Ian | |
| Autor | McIlleron, Helen | |
| Autor | Havlir, Diane V. | |
| Autor | Haas, David W. | |
| Fecha de acceso | 2018-10-11T18:27:44Z | |
| Fecha de disponibilización | 2018-10-11T18:27:44Z | |
| Fecha de publicación | 2015 | |
| Referencia | LUETKEMEYER, Anne F. et al. Combined Effect of CYP2B6 and NAT2 Genotype on Plasma Efavirenz Exposure During Rifampin-Based Antituberculosis Therapy in the STRIDE Study. Clinical Infectious Diseases, v. 60, n. 12, p. 1860-1863, Jun. 2015. | pt_BR |
| ISSN | 1058-4838 | pt_BR |
| URI | https://www.arca.fiocruz.br/handle/icict/29549 | |
| Descripción | Adult AIDS Clinical Trials Group A5221 and A5243 Study Teams. | |
| Promoción | Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the NIH under Award Numbers UM1 AI068634, UM1 AI068636 and UM1 AI106701. Additional grant support included AI077505, TR000445 (D. W. H.) and National Research Foundation of South Africa 90729 (H. M.). Antiretroviral medications were donated by Gilead Sciences and Merck Pharmaceuticals. | |
| Idioma | eng | pt_BR |
| Editor | Oxford | |
| Derechos de autor | open access | pt_BR |
| Título | Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study | pt_BR |
| Tipo del documento | Article | pt_BR |
| DOI | 10.1093/cid/civ155 | |
| Resumen en Inglés | In STRIDE, slow metabolizer CYP2B6 and NAT2 genotypes were each associated with increased plasma efavirenz concentrations during antituberculosis therapy. Concentrations were greater on therapy than off therapy in 58% with CYP2B6 and 93% with NAT2 slow metabolizer genotypes. Individuals with slow metabolizer genotypes in both genes had markedly elevated concentrations. | pt_BR |
| Afiliación | University of California. San Francisco General Hospital. HIV/AIDS Division. San Francisco, USA. | pt_BR |
| Afiliación | Harvard School of Public Health. Center for Biostatistics in AIDS Research. Boston, Massachusetts, USA. | pt_BR |
| Afiliación | Harvard School of Public Health. Center for Biostatistics in AIDS Research. Boston, Massachusetts, USA. | pt_BR |
| Afiliación | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Afiliación | IMPACTA. Lima, Peru. | pt_BR |
| Afiliación | Joint Clinical Research Center. Kampala, Uganda. | pt_BR |
| Afiliación | University of the Witwatersrand. Faculty of Health Sciences. Johannesburg, South Africa. | pt_BR |
| Afiliación | University of Cape Town. Department of Medicine. Division of Clinical Pharmacology Cape Town, South Africa. | pt_BR |
| Afiliación | University of California. San Francisco General Hospital. HIV/AIDS Division. San Francisco, USA. | pt_BR |
| Afiliación | Vanderbilt University School of Medicine. Department of Medicine. Nashville, Tennessee, USA. | pt_BR |
| Palavras clave en Inglês | HIV/AIDS | pt_BR |
| Palavras clave en Inglês | Efavirenz | pt_BR |
| Palavras clave en Inglês | Pharmacogenetic | pt_BR |
| Palavras clave en Inglês | Rifampin | pt_BR |
| Palavras clave en Inglês | Tuberculosis | pt_BR |
| e-ISSN | 1537-6591 |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
INI - Artigos de Periódicos [3646]